scholarly journals Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort

2019 ◽  
Vol 27 (3) ◽  
pp. 149-159
Author(s):  
Tiago Pereira Guedes ◽  
Pedro Fragoso ◽  
Carolina Lemos ◽  
Mónica Garrido ◽  
Joana Silva ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis C ◽  
Real World ◽  
Response To Treatment ◽  
Direct Acting Antivirals ◽  
Advanced Liver Disease ◽  
Long Term Follow Up ◽  
Direct Acting

scholarly journals Long term follow up after HCV cure with direct acting antivirals – review of the literature

2018 ◽  
Vol 21 (4) ◽  
pp. 167-171
Author(s):  
Andreea Ruxandra Cazan ◽  
◽  
George Sebastian Gherlan ◽  
Raluca Mihaela Dîrtu ◽  
Simin Aysel Florescu ◽  
...  
Keyword(s):  
Review Of The Literature ◽  
Direct Acting Antivirals ◽  
Long Term Follow Up ◽  
Direct Acting

scholarly journals Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy

2020 ◽  
Author(s):  
Raissa M Arruda ◽  
Andrea D Batista ◽  
Norma A Filgueira ◽  
Izolda F Moura ◽  
Luis H Sette ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Side Effects ◽  
Renal Diseases ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
Autoimmune Phenomena

Abstract In addition to liver disease, the hepatitis C virus (HCV) has been associated with autoimmune phenomena, such as mixed cryoglobulin and glomerulonephritis (GN). Until recently, both chronic hepatitis and HCV extra-hepatic manifestations were treated with peg-interferon plus ribavirin, however these drugs presented low efficacy and induced severe side effects. Nowadays, the HCV chronic hepatitis has been treated with direct acting antivirals (DAA), but studies on the DAA therapy for HCV-associated glomerulonephritis are scarce. Here, we describe two cases of HCV-associated glomerulonephritis that were treated with DAAs. In these two cases, previously experienced to peg-interferon plus ribavirin, the sofosbuvir plus simeprevir therapy was effective, without significant side effects, and interrupted the evolution of at least 20 years of both hepatic and renal diseases. These cases join the seven previously described cases that were treated with this DAAs association.

scholarly journals Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure

2015 ◽  
Vol 41 (6) ◽  
pp. 532-543 ◽  
Author(s):  
M. Hedenstierna ◽  
O. Weiland ◽  
A. Brass ◽  
D. Bankwitz ◽  
P. Behrendt ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Immune Responses ◽  
Long Term Follow Up

scholarly journals Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Maria Giovanna Quaranta ◽  
Luigina Ferrigno ◽  
Xhimi Tata ◽  
Franca D’Angelo ◽  
Carmine Coppola ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Liver Disease ◽  
Liver Function ◽  
Previous History ◽  
Direct Acting Antivirals ◽  
Advanced Liver Disease ◽  
Cox Regression Analysis ◽  
Viral Eradication ◽  
Direct Acting

Abstract Background The development of direct-acting antivirals (DAA) for HCV has revolutionized the treatment of HCV, including its treatment in patients with HIV coinfection. The aim of this study was to compare the changes in liver function between coinfected and monoinfected patients with cirrhosis who achieved HCV eradication by DAA. Methods Patients with pre-treatment diagnosis of HCV liver cirrhosis, consecutively enrolled in the multicenter PITER cohort, who achieved a sustained virological response 12 weeks after treatment cessation (SVR12) were analysed. Changes in Child-Pugh (C-P) class and the occurrence of a decompensating event was prospectively evaluated after the end of DAA treatment. Cox regression analysis was used to evaluate factors independently associated with changes in liver function following viral eradication. Results We evaluated 1350 patients, of whom 1242 HCV monoinfected (median follow-up 24.7, range 6.8–47.5 months after viral eradication) and 108 (8%) HCV/HIV coinfected (median follow-up 27.1, range 6.0–44.6). After adjusting for age, sex, HCV-genotype, HBsAg positivity and alcohol use, HIV was independently associated with a more advanced liver disease before treatment (C-P class B/C vs A) (OR: 3.73, 95% CI:2.00–6.98). Following HCV eradication, C-P class improved in 17/20 (85%) coinfected patients (from B to A and from C to B) and in 53/82 (64.6%) monoinfected patients (from B to A) (p = 0.08). C-P class worsened in 3/56 coinfected (5.3%) (from A to B) and in 84/1024 (8.2%) monoinfected patients (p = 0.45) (from A to B or C and from B to C). Baseline factors independently associated with C-P class worsening were male sex (HR = 2.00; 95% CI = 1.18–3.36), platelet count < 100,000/μl (HR = 1.75; 95% CI 1.08–2.85) and increased INR (HR = 2.41; 95% CI 1.51–3.84). Following viral eradication, in 7 of 15 coinfected (46.6%) and in 61 of 133 (45.8%) monoinfected patients with previous history of decompensation, a new decompensating event occurred. A first decompensating event was recorded in 4 of 93 (4.3%) coinfected and in 53 of 1109 (4.8%) monoinfected patients (p = 0.83). Conclusions Improvement of liver function was observed following HCV eradication in the majority of patients with cirrhosis; however viral eradication did not always mean cure of liver disease in both monoinfected and coinfected patients with advanced liver disease.

Sign in / Sign up

Export Citation Format

Share Document